Design, synthesis and biological evaluation of novel tetrahydroisoquinoline derivatives as P-glycoprotein-mediated multidrug resistance inhibitors

被引:16
作者
Gao, Yang [1 ]
Shi, Wei [2 ]
Cui, Jian [2 ]
Liu, Chunxia [2 ]
Bi, Xinzhou [2 ]
Li, Zhuo [2 ]
Huang, Wenlong [2 ,3 ]
Wang, Guangji [1 ]
Qian, Hai [2 ,3 ]
机构
[1] China Pharmaceut Univ, Key Lab Drug Metab & Pharmacokinet, Nanjing 210009, Jiangsu, Peoples R China
[2] China Pharmaceut Univ, Ctr Drug Discovery, State Key Lab Nat Med, 24 Tongjiaxiang, Nanjing 210009, Jiangsu, Peoples R China
[3] China Pharmaceut Univ, Jiangsu Key Lab Drug Discovery Metab Dis, 24 Tongjiaxiang, Nanjing 210009, Jiangsu, Peoples R China
基金
美国国家科学基金会;
关键词
Cancer; Multidrug resistance; P-glycoprotein; Reversal agents; MDR MODULATORS; GP INHIBITORS; CANCER-CELLS; TRANSPORTERS; EFFLUX; ANALOGS; FAMILY; AGENTS;
D O I
10.1016/j.bmc.2018.03.045
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Multidrug resistance (MDR) is one of the main obstacles of clinical chemotherapy. A great deal of research shows that the occurrence of drug resistance in various malignant tumors is closely related to the expression of P-glycoprotein (P-gp) on the surface of the cell membrane. In this paper, based on the structure-activity relationship of phenylethyl tetrahydroisoquinoline, we choose tariquidar as the lead compound for the design and synthesis of 17 novel tetrahydroisoquinoline P-gp inhibitors. Additionally, in vitro and in vivo cytotoxicity assays and reversed MDR activity assays were evaluated. Among them, compound 3 had a good reversal of MDR activity and the reversal mechanism study of it was carried out. All of these results demonstrated that compound 3 was considered to be a promising P-gp-mediated MDR reversal candidate. (C) 2018 Elsevier Ltd. All rights reserved.
引用
收藏
页码:2420 / 2427
页数:8
相关论文
共 27 条
[1]   Promising Therapy of XDR-TB/MDR-TB with Thioridazine an Inhibitor of Bacterial Efflux Pumps [J].
Amaral, L. ;
Martins, M. ;
Viveiros, M. ;
Molnar, J. ;
Kristiansen, J. E. .
CURRENT DRUG TARGETS, 2008, 9 (09) :816-819
[2]   Development of small-molecule P-gp inhibitors of the N-benzyl 1,4-dihydropyridine type: Novel aspects in SAR and bioanalytical evaluation of multidrug resistance (MDR) reversal properties [J].
Baumert, Christiane ;
Guenthel, Marianne ;
Krawczyk, Soeren ;
Hemmer, Marc ;
Wersig, Tom ;
Langner, Andreas ;
Molnar, Josef ;
Lage, Hermann ;
Hilgeroth, Andreas .
BIOORGANIC & MEDICINAL CHEMISTRY, 2013, 21 (01) :166-177
[3]   Recent Advances in the Development of P-gp Inhibitors [J].
Baumert, Christiane ;
Hilgeroth, Andreas .
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2009, 9 (04) :415-436
[4]   A family of drug transporters: The multidrug resistance-associated proteins [J].
Borst, P ;
Evers, R ;
Kool, M ;
Wijnholds, J .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2000, 92 (16) :1295-1302
[5]   The JAK2 inhibitors CEP-33779 and NVP-BSK805 have high P-gp inhibitory activity and sensitize drug-resistant cancer cells to vincristine [J].
Cheon, Ji Hyun ;
Kim, Kyeong Seok ;
Yadav, Dharmendra Kumar ;
Kim, Mihyun ;
Kim, Hyung Sik ;
Yoon, Sungpil .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2017, 490 (04) :1176-1182
[6]   Diphenyleyclohexylamine derivatives as new potent multidrug resistance (MDR) modulators [J].
Dei, S ;
Budriesi, R ;
Sudwan, P ;
Ferraroni, M ;
Chiarini, A ;
Garnier-Suillerot, A ;
Manetti, D ;
Martelli, C ;
Scapecchi, S ;
Teodori, E .
BIOORGANIC & MEDICINAL CHEMISTRY, 2005, 13 (04) :985-998
[7]   Design and synthesis of aminoester heterodimers containing flavone or chromone moieties as modulators of P-glycoprotein-based multidrug resistance (MDR) [J].
Dei, Silvia ;
Romanelli, Maria Novella ;
Manetti, Dina ;
Chiaramonte, Niccolo ;
Coronnello, Marcella ;
Salerno, Milena ;
Teodori, Elisabetta .
BIOORGANIC & MEDICINAL CHEMISTRY, 2018, 26 (01) :50-64
[8]   Medicinal attributes of 1,2,3-triazoles: Current developments [J].
Dheer, Divya ;
Singh, Virender ;
Shankar, Ravi .
BIOORGANIC CHEMISTRY, 2017, 71 :30-54
[9]   SURFACE GLYCOPROTEIN MODULATING DRUG PERMEABILITY IN CHINESE-HAMSTER OVARY CELL MUTANTS [J].
JULIANO, RL ;
LING, V .
BIOCHIMICA ET BIOPHYSICA ACTA, 1976, 455 (01) :152-162
[10]   Salinomycin enhances doxorubicin-induced cytotoxicity in multidrug resistant MCF-7/MDR human breast cancer cells via decreased efflux of doxorubicin [J].
Kim, Kwang-Youn ;
Kim, Sang-Hun ;
Yu, Sun-Nyoung ;
Park, Suel-Ki ;
Choi, Hyeun-Deok ;
Yu, Hak-Sun ;
Ji, Jae-Hoon ;
Seo, Young-Kyo ;
Ahn, Soon-Cheol .
MOLECULAR MEDICINE REPORTS, 2015, 12 (02) :1898-1904